Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety.

ABSTRACT: Amlodipine is an antihypertensive drug with unknown pharmacogenetic biomarkers. This research is a candidate gene study that looked for associations between amlodipine pharmacokinetics and safety and pharmacogenes. Pharmacokinetic and safety data were taken from 160 volunteers from eight bioequivalence trials. In the exploratory step, 70 volunteers were genotyped for 44 polymorphisms in different pharmacogenes. CYP2D6 poor metabolizers (PMs) showed higher half-life (t_1/2) (univariate p-value (p_uv) = 0.039, multivariate p-value (p_mv) = 0.013, β = -5.31, R² = 0.176) compared to ultrarapid (UMs), normal (NMs) and intermediate metabolizers (IMs). SLC22A1 rs34059508 G/A genotype was associated with higher dose/weight

SUBMITTER: Soria-Chacartegui P 

PROVIDER: S-EPMC9959242 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature